Patho-physiological analysis for the mechanism of neonatal haemostatic and neonatal thrombosis, and exploration of the new therapeutic approach

新生儿止血及新生儿血栓形成机制的病理生理分析及治疗新途径的探索

• 批准号: 14571055
• 负责人: TAKAHASHI Yukihiro
• 金额: $ 2.18万
• 依托单位: NARA MEDICAL UNIVERSITY
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571055/
• 关键词: NEONATE; HAEMOSTASIS; THROMBOSIS; ACTIVATED FACTOR VII; THROMBELASTOGRAPH; VON WILEBRAND FACTOR; ECTO-ATPASE; ANTI-THROMBOTIC NEONATAL CENTRAL CATHETER; 止血機構; 播種性血管内凝固(DIC); FVIIa; 線溶; TAFI; フォン・ヴィレブランド因子切断酵素; 中心静脈カテーテル; 播種性血管内凝固; Von Will

We studied the following subjects for the pathophysiological understanding of the neonatal haemostasis and thrombosis as described in the application of Grand-in-Aid for scientific research. The first, we performed a retrospective study on neonatal DIC and also examined into the effectiveness of commercial available anti-protease peptides. The second, we studied the haemostatic mechanism in neonate by thrombelastogragh, using adult bloods mixed with a very small amount of thrombin or ADP, recombinant activated factor VII (FYIIa). And we examined the effect of several kinds of anti-thrombotic drugs, such as antithrombin, activated protein C, thrombomodulin, anti-thrombotic peptides using thrombelastograph. Furthermore, we analysed the haemostatic mechanism of recombinant activated factor VII using several kinds of coagulation factor-deficient plasmas and artificial, reduced platelet blood. And we understood the haemostatic mechanism of FVIIa and also found that platelets were one of key factors for haemostasis induced by FVIIa. The third, we studied a ecto-ATPase activity in umbilical cord bloods and found that it was important for anti-thrombotic effects on neonatal haemostasis. The fourth, we verified the activity of von Willebrand factor cleaving protease in cord bloods from premature to mature babies. And we studied on anti thrombotic neonatal central catheter using cord bloods under shear stress condition.

我们研究了以下对象对新生儿止血和血栓形成的病理生理理解，如应用宏伟的科学研究所述。首先，我们对新生儿DIC进行了回顾性研究，并研究了商业可用抗蛋白酶肽的有效性。第二，我们使用成年血液与少量凝血酶或ADP混合的成年血液研究了新生儿的止血机制，重组激活因子VII（FYIIA）。我们研究了使用血小板仪的几种抗凝血药物，例如抗凝血酶，活化蛋白C，血小板结合蛋白，抗血栓形成肽的效果。此外，我们使用几种缺乏凝结因子的等离子体和人工，减少的血小板血液分析了重组激活因子VII的止血机制。我们了解了FVIIA的止血机制，还发现血小板是FVIIA诱导的止血的关键因素之一。第三，我们研究了脐带血液中的肾上腺ATPase活性，发现它对于对新生儿止血的抗脉止性影响很重要。第四，我们验证了von Willebrand因子在脐带血到成熟婴儿中蛋白酶切割蛋白酶的活性。我们使用剪切应力条件下的脐带血研究了抗血栓新生儿中央导管。

项目成果

Clilnical Effect of Nafamostat Mesilate for Disseminated Intravascular Coagulation of Neonate -The comparison with Gabexate Mesilate-

甲磺酸萘莫司他治疗新生儿弥散性血管内凝血的临床效果-与甲磺酸加贝酯的比较-

• 发表时间: 2004
• 期刊: Japanese Journal of Pediatric Hematology 18
• 作者: Hanaesak Y;Takahashi Y;Kawaguchi C;Morikawa H.;Yashihara H;Yoshida K;Yoshioka A.
• 通讯作者: Yoshioka A.

白幡 聡(他14名): "新生児低プロトロンビン血症に対するケイツーN注の有効性および安全性の検討"日本未熟児新生児学会雑誌. 16(1). 53-62 (2004)

Satoshi Shirahata（和其他 14 人）：“K2-N 注射治疗新生儿低凝血酶原血症的有效性和安全性评估”，日本早产儿和新生儿学会杂志 16(1) (2004)。

The Abnormality of Fibrinolytic System

纤溶系统异常

• 发表时间: 2003
• 期刊: Dinamic Medicine (Nishimura Pub.) Vol 3
• 作者: Takahashi Y;Akira Y.
• 通讯作者: Akira Y.

先天性plasminogen activator inhibitor-1欠乏症患者の智歯抜糸術の麻酔経験.

先天性纤溶酶原激活物抑制剂-1缺乏症患者拔智齿的麻醉经验

• 发表时间: 2003
• 期刊: 麻酔 53
• 作者: Shirahata;A;Chida S;Tamura M;Nishida H;Tada H;Horicuhi T;Goto A;Inukai K;Funato M;Fujimura M;Kinoshita Y;Takahashi Y;Nakamura H;Yamuchi Y;Ibara S;梶原淳久
• 通讯作者: 梶原淳久

新生児の播種性血管内凝固に対するメシル酸ナファモスタート(Futhan)の治療効果-メシル酸ガベキサート(FOY)との比較

甲磺酸萘莫司特（Futhan）对新生儿弥散性血管内凝血的治疗效果——与甲磺酸加贝酯（FOY）的比较

• 发表时间: 2004
• 期刊: 日本小児血液学会誌 18
• 作者: 塙坂八重